159 related articles for article (PubMed ID: 22169801)
1. Tumorigenesis: Testing ground for cancer stem cells.
Delude C
Nature; 2011 Dec; 480(7377):S43-5. PubMed ID: 22169801
[No Abstract] [Full Text] [Related]
2. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
[No Abstract] [Full Text] [Related]
3. Cancer stem cells in multiple myeloma.
Ghosh N; Matsui W
Cancer Lett; 2009 May; 277(1):1-7. PubMed ID: 18809245
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
[TBL] [Abstract][Full Text] [Related]
5. Perspective: A model disease.
Matsui W
Nature; 2011 Dec; 480(7377):S58. PubMed ID: 22169808
[No Abstract] [Full Text] [Related]
6. Understanding myeloma cancer stem cells.
Pascutti F; Cunha LL; Rizzatti EG; Colleoni GW
Immunotherapy; 2013 Dec; 5(12):1291-4. PubMed ID: 24283839
[No Abstract] [Full Text] [Related]
7. In vitro cloning and chemosensitivity of human myeloma stem cells.
Salmon SE
Clin Haematol; 1982 Feb; 11(1):47-63. PubMed ID: 6176384
[No Abstract] [Full Text] [Related]
8. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis.
Pfeifer S; Perez-Andres M; Ludwig H; Sahota SS; Zojer N
Leukemia; 2011 Jul; 25(7):1213-6. PubMed ID: 21494259
[No Abstract] [Full Text] [Related]
10. Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents.
Kim KH; Cheong HJ; Lee MY; Lee N; Lee KT; Park SK; Won JH
Anticancer Res; 2019 Jan; 39(1):127-133. PubMed ID: 30591449
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.
Winquist RJ; Boucher DM; Wood M; Furey BF
Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800
[TBL] [Abstract][Full Text] [Related]
12. The clinical and therapeutic implications of cancer stem cell biology.
Cheng L; Alexander R; Zhang S; Pan CX; MacLennan GT; Lopez-Beltran A; Montironi R
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1131-43. PubMed ID: 21806335
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
14. [PET-CT studies of metastasizing cancer of the colon and rectum. Variability of tumor aggressiveness as a micro-evolutionary process of cancer stem cells with predetermined prognosis].
Stelzner F; von Mallek D; Ruhlmann J; Biersack HJ
Chirurg; 2009 Jul; 80(7):645-51. PubMed ID: 19562240
[TBL] [Abstract][Full Text] [Related]
15. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
16. A serum-free culture method for myeloma progenitors in vitro: proliferative and immunophenotypic characteristics.
Rhodes EG; Olive C; Flynn MP
Exp Hematol; 1990 Feb; 18(2):79-83. PubMed ID: 2406157
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Niesvizky R; Mark TM; Ward M; Jayabalan DS; Pearse RN; Manco M; Stern J; Christos PJ; Mathews L; Shore TB; Zafar F; Pekle K; Xiang Z; Ely S; Skerret D; Chen-Kiang S; Coleman M; Lane ME
Clin Cancer Res; 2013 Mar; 19(6):1534-46. PubMed ID: 23357980
[TBL] [Abstract][Full Text] [Related]
18. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors in multiple myeloma].
Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede P; Palumbo A; Pileri A
Haematologica; 1989 Oct; 74(5 Suppl):347-57. PubMed ID: 2512219
[No Abstract] [Full Text] [Related]
20. Clonogenic myeloma cells and chemotherapy.
Peest D; Deicher H
Lancet; 1989 Jan; 1(8628):51. PubMed ID: 2563036
[No Abstract] [Full Text] [Related]
[Next] [New Search]
